Physician

Mark Matson Kaehr, MD

According to 2025 Medicare claims, Mark Kaehr, MD (NPI: 1427361450) practices ophthalmology in the Indianapolis-Carmel-Greenwood, IN market, with the plurality of this provider's patient population coming from Hendricks, IN. This provider's primary affiliated billing organization is ASSOCIATED VITREORETINAL & UVEITIS CONSULTANTS LLC (NPI: 1043270309; TIN: 351497551) and primary practice location at 46032-5422.

Kaehr's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 964 traditional Medicare patients, billed 35,176 HCPCS/CPT codes, and received $2,969,444 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 679 prescription claims across 232 beneficiaries totaling $269,039 in drug costs, led by Humira(Cf) Pen (Adalimumab). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $148,232 to $2,969,444. Similarly, Part D prescription costs have risen steadily, from $14,342 to $269,039. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.5M$3.0M2015 Medicare payment: $148,232 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $223,488 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $845,258 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,394,175 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,850,674 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,227,983 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,651,486 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,788,461 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,799,179 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,969,444 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015155724$148,232
20165151,839$223,488
20177796,450$845,258
20189148,135$1,394,175
20191,06210,285$1,850,674
20201,07110,687$2,227,983
20211,19412,406$2,651,486
20221,09217,204$2,788,461
20231,02830,591$2,799,179
202496435,176$2,969,444

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$243K$486K2015 Drug cost: $14,342 (USD; Tot_Drug_Cst)2016 Drug cost: $14,703 (USD; Tot_Drug_Cst)2017 Drug cost: $123,969 (USD; Tot_Drug_Cst)2018 Drug cost: $324,954 (USD; Tot_Drug_Cst)2019 Drug cost: $351,790 (USD; Tot_Drug_Cst)2020 Drug cost: $349,192 (USD; Tot_Drug_Cst)2021 Drug cost: $430,828 (USD; Tot_Drug_Cst)2022 Drug cost: $415,878 (USD; Tot_Drug_Cst)2023 Drug cost: $486,047 (USD; Tot_Drug_Cst)2024 Drug cost: $269,039 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201574243$14,342
201691233$14,703
2017219724$123,969
2018269861$324,954
2019296909$351,790
2020274926$349,192
2021258872$430,828
2022231785$415,878
2023192641$486,047
2024232679$269,039

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg2982,530$652
67028Injection of drug into eye4041,768$90
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more423592$61
92134Imaging of retina8682,493$29
92202Extended exam of the back part of the eye with optic nerve drawing349487$11

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Humira(Cf) PenAdalimumab18504$137,066
Prednisolone AcetatePrednisolone Acetate1748,657$7,917
DifluprednateDifluprednate662,544$7,560
SimbrinzaBrinzolamide/Brimonidine Tart11519$2,908
ValacyclovirValacyclovir Hcl21850$2,175

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Mark Matson Kaehr, MD?

Tedicare shows public-source Medicare data for Mark Matson Kaehr, MD (NPI 1427361450), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Matson Kaehr, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Matson Kaehr, MD?

Mark Matson Kaehr, MD is linked to ASSOCIATED VITREORETINAL & UVEITIS CONSULTANTS LLC (billing NPI 1043270309) in the available physician profile data.

Does Mark Matson Kaehr, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.